Search Results 101-110 of 17302 for egfr

  1. MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) - Mayo Clinic

    ... EGFR containing regimens. The primary purpose of this study for Step 2: To assess the anti-tumour activity of MEN1611 in combination with cetuximab in ...

  2. FORTIFI-HN01: A Study Of Ficerafusp Alfa (BCA101) Or Placebo In Combination With Pembrolizumab In First-Line PD-L1-pos, R Or M HNSCC - Mayo Clinic

    Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to ...

  3. Clinical trials - Oncology (Medical)

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  4. Clinical trials - Oncology (Medical)

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  5. Pulmonary Medicine Clinical Trials - Medical Professionals

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  6. A Study of Erlotinib as a Prevention in Trisomy 7 Positive Primary Sclerosing Cholangitis - Mayo Clinic

    Erlotinib (Tarceva) is a human EGFR type 1 tyrosine kinase inhibitor and offers greater survival benefit to EGFR positive patients. This study will assist ...

  7. Pulmonary Medicine Clinical Trials - Medical Professionals

    ... EGFR mutant population. Patients will be enrolled over a three year period across approximately 25 geographically diverse academic as well as community ...

  8. Clinical trials - Oncology (Medical)

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  9. Clinical trials - Oncology (Medical)

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  10. Phase II Single-arm Study of Tepotinib Combined with Cetuximab - Mayo Clinic

    ... (EGFR) antibody targeted therapy due to mesenchymal epithelial transition factor (MET) amplification. Participation eligibility. Participant eligibility ...